tradingkey.logo

Kezar Life Sciences Inc <KZR.OQ> expected to post a loss of $2.88 a share - Earnings Preview

ReutersMar 10, 2025 11:18 AM
  • Kezar Life Sciences Inc KZR.OQ KZR.O is expected to show no change in quarterly revenue when it reports results on March 12 (estimated) for the period ending December 31 2024

  • ​LSEG's mean analyst estimate for Kezar Life Sciences Inc is for a loss of $2.88 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Kezar Life Sciences Inc is $13.50​, above​ its last closing price of $6.10. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-3.27

-3.15

-2.78

Beat

11.7

Jun. 30 2024

-3.39

-3.20

-2.70

Beat

15.7

Mar. 31 2024

-3.33

-3.33

-3.00

Beat

9.9​

Dec. 31 2023

-4.30

-3.80

-4.40

Missed

-15.8

​​Sep. 30 2023

-3.58

-3.49

-3.20

Beat

8.4

Jun. 30 2023

-3.21

-3.20

-3.40

Missed

-6.2​

Mar. 31 2023

-2.90

-2.88

-3.10

Missed

-7.5

Dec. 31 2022

-2.76

-2.50

Beat

9.6

This summary was machine generated March 10 at 11:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI